; and (C) to provide for ongoing surveillance sufficient to support contact tracing, case identification, quarantine, and isolation to prevent future outbreaks of COVID–19; (2) specific plans and benchmarks, each with clear timelines, to ensure— (A) such level of, types of, and approaches to testing as are described in paragraph (1), with respect to optimizing health and safety; (B) sufficient availability of all necessary testing materials and supplies, including extraction and testing kits, reagents, transport media, swabs, instruments, analysis equipment, personal protective equipment if necessary for testing (including point-of-care testing), and other equipment; (C) allocation of testing materials and supplies in a manner that optimizes public health, including by considering the variable impact of SARS–CoV–2 on specific States, territories, Indian Tribes, Tribal organizations, urban Indian organizations, communities, industries, and professions; (D) sufficient evidence of validation for tests that are deployed as a part of such strategy; (E) sufficient laboratory and analytical capacity, including target turnaround time for test results; (F) sufficient personnel, including personnel to collect testing samples, conduct and analyze results, and conduct testing follow-up, including contact tracing, as appropriate; and (G) enforcement of the Families First Coronavirus Response Act ( Public Law 116–127 ) to ensure patients who are tested are not subject to cost sharing; (3) specific plans to ensure adequate testing in rural areas, frontier areas, health professional shortage areas, and medically underserved areas (as defined in section 330I(a) of the Public Health Service Act ( 42 U.S.C. 254c–14(a) )), and for underserved populations, Native Americans (including Indian Tribes, Tribal organizations, and urban Indian organizations), and populations at increased risk related to COVID–19